Skip to main navigation
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Contact
  • Programs
    • HBV
    • Pipeline
  • Patients
    • Commitment
    • Clinical Trials
    • Resources
  • Sustainability
    • Overview
    • Business Ethics
    • Access to Health Care
    • Human Capital
    • Environment, Health and Safety
  • Collaborations
  • Investors
    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Financials & Filings
    • Stock Information
  • Careers
    • Culture
    • Benefits
    • Opportunities
On the

Investor Relations

Corporate Profile

Assembly Bio aspires to deliver finite and curative therapies for chronic hepatitis B virus (HBV) infection, one of the world’s most prevalent and devastating infectious diseases.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases

See all news
  • Assembly Biosciences Announces Promising Interim Results from Two Clinical Trials Evaluating Highly Potent Next-Generation Core Inhibitor Candidates ABI-H3733 and ABI-4334
  • Assembly Biosciences Doses First Subject in Phase 1a Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of Investigational Next Generation Core Inhibitor ABI-4334
  • Assembly Biosciences Reports Third Quarter 2022 Financial Results and Recent Highlights and Announces Upcoming Conference Participation

Events &
Presentations

See all upcoming events
  • Nov 15, 2022 at 12:35 PM EST
    Jefferies London Healthcare Conference – Fireside Chat
  • Nov 4 - Nov 8, 2022
    AASLD – The Liver Meeting 2022
  • Oct 18, 2022 from 12:00 PM to 12:30 PM EDT
    H.C. Wainwright 3rd Annual Hepatitis B Virus (HBV) Virtual Conference
Shareholder Tools Print Email Alerts Printed Materials RSS News Feeds
Search Investors

Contact Us

833.509.4583
info@assemblybio.com
LinkedIn
About Programs Patients Collaborations Investors Careers

© 2023 Assembly Biosciences, Inc.